THE NICKLES GROUP, LLC for AMGEN
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Monitored implementation of P.L. 117-169, the Inflation Reduction Act as it relates to drug pricing. Issues related to biosimilars. Issues related to cardiovascular care. Monitored issues related to pharmacy benefit management.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRETT BAKER | — |
| GREG D'ANGELO | — |
| MARY BETH SAVARY TAYLOR | — |
Health Issues HCR
Monitored issues related to pharmacy benefit management.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRETT BAKER | — |
| GREG D'ANGELO | — |
| MARY BETH SAVARY TAYLOR | — |
Copyright/Patent/Trademark CPT
S. 79, Interagency Patent Coordination and Improvement Act of 2023. S. 150, Affordable Prescriptions for Patients Act of 2023. Issues concerning mergers and acquisitions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRETT BAKER | — |
| JEFF CHOUDHRY | — |
| GREG D'ANGELO | — |
Taxation/Internal Revenue Code TAX
S. 866, the American Innovation & Jobs Act and H.R. 3938, Build It in America Act, and issues related to the R&D tax credit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| RACHEL JONES HENSLER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.